Details

Autor(en) / Beteiligte

• Ide, Daisuke
• Fujino, Takahiro
• Kobayashi, Tsutomu
• Egashira, Aya
• Miyashita, Akihiro
• Mizuhara, Kentaro
• Isa, Reiko
• Tsukamoto, Taku
• Mizutani, Shinsuke
• Uchiyama, Hitoji
• Kaneko, Hiroto
• Uoshima, Nobuhiko
• Kawata, Eri
• Taniwaki, Masafumi
• Shimura, Yuji
• Kuroda, Junya

Titel

Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio

Ist Teil von

• International journal of hematology, 2024-06, Vol.119 (6), p.697-706

Ort / Verlag

Singapore: Springer Nature Singapore

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• We conducted a multi-institutional retrospective study in 100 transplant-ineligible (TI) patients with diffuse large B-cell lymphoma (DLBCL) that relapsed or progressed after first-line R-CHOP (or -like) therapy to develop a robust predictive model for TI relapsed/refractory (r/r) DLBCL, which has a heterogeneous but poor prognosis by currently available treatment modalities other than chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies. The median age at relapse or progression was 76 years. The median progression-free survival (PFS) and overall survival (OS) from the first progression were 11.5 months and 21.9 months, respectively. Multivariate analysis identified low lymphocyte-to-monocyte ratio (LMR), elevated high lactate dehydrogenase, and elevated C-reactive protein at progression as independent predictors of OS. A predictive model based on these three factors, here designated as the Kyoto Prognostic Index for r/r DLBCL (KPI-R), successfully stratified their OS and PFS with statistical significance. In addition, event-free survival less than 24 months for R-CHOP and low LMR were identified as significant predictive factors for non-response in any sequence of salvage therapy. We concluded that LMR is a bonafide predictor of treatment response and prognosis in patients with TI r/r DLBCL, and may be helpful in treatment decision-making.